Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone used, without approval, to induce tanning. It is one of the more widely used unapproved peptides and carries the clearest documented safety concern in this formulary.
This guide situates Melanotan II within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
How Melanotan II works
Skin pigmentation is regulated by alpha-MSH acting at the melanocortin-1 receptor (MC1R) on melanocytes. Activation shifts melanin synthesis toward eumelanin, the darker pigment, producing tanning without requiring ultraviolet exposure.
Melanotan II is a synthetic alpha-MSH analog engineered for stability and potency. Critically, it is non-selective across melanocortin receptor subtypes: besides MC1R, it activates MC4R, which is involved in appetite regulation and sexual function, and MC3R and MC5R.
That non-selectivity explains its full effect profile — tanning from MC1R, plus appetite suppression, nausea, spontaneous erections and increased libido from MC4R. It also explains a related molecule: bremelanotide (PT-141), a metabolite of Melanotan II, which was developed specifically for the sexual-function effect and did reach approval.
The dermatologic safety concern
The central concern is direct and mechanistic. Melanotan II stimulates melanocytes, and that stimulation is not confined to normal background skin — it acts on existing melanocytic nevi as well.
The documented consequences include darkening of existing moles, enlargement of nevi, and the appearance of new pigmented lesions. These are consistently reported in the clinical literature on Melanotan II users.
More seriously, there are published case reports of melanoma diagnosed in Melanotan II users, including cases where a lesion changed during or after use. Dermatology literature has repeatedly raised this association.
Causality requires care. Case reports cannot establish that the drug caused the melanoma, and users may share other risk factors including a desire for tanned skin and prior UV exposure. But there is no reassuring interpretation available either: a compound that stimulates melanocyte activity, that demonstrably alters existing nevi, and that is associated with case reports of melanoma is not one whose safety can be assumed.
There is a further practical harm. Because the drug changes the appearance of moles, it interferes with the visual surveillance that detects melanoma early. A lesion changing because of the drug and a lesion changing because it is malignant are difficult to distinguish, which undermines the primary screening tool.
Other reported effects
Commonly reported effects include nausea, particularly after early doses, facial flushing, appetite suppression, and spontaneous erections in men.
Priapism — prolonged erection — has been reported and is a urologic emergency requiring immediate treatment to prevent permanent damage.
Because these products are unregulated research chemicals, identity, purity, sterility and dose are unverified, adding contamination and dosing risk to the pharmacologic risks above. Injection-site infections have been reported.
Regulatory status — stated precisely
Melanotan II is not approved in the United States or elsewhere for tanning or any other indication. Multiple regulators internationally have issued specific warnings against its use.
It was among the twelve peptides removed from FDA Category 2 on April 15, 2026. As our PEG-MGF guide sets out, removal from Category 2 is not approval — it lifts a safety-risk designation pending further evaluation and does not place a substance on the 503A bulks list. Given the dermatologic concerns above, presenting that change as validation would be seriously misleading.
For clinicians, the practical action is straightforward: ask about it, because patients rarely volunteer it, and any patient using or having used Melanotan II warrants a full skin examination and dermatology referral for any changing lesion. Patients seeking a tanned appearance should be directed to sunless tanning products, which carry none of this risk.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering melanocortin pharmacology and dermatologic risk, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →